地塞米松联合抗炎、抗感染治疗虹膜睫状体炎的有效性观察

Efficacy of Dexamethasone Combined with Anti Inflammation and Anti Infection in the Treatment of Iridocyclitis

目的:分析地塞米松联合抗炎、抗感染治疗在虹膜睫状体炎中的应用价值。方法:选取2016年7月至2018年7月期间52例虹膜睫状体炎患者,按照入院登记顺序随机分为参照组、研究组,各26例,参照组术后单纯予以地塞米松处理,研究组术后予以地塞米松联合抗炎、抗感染处理,对比效果。结果:研究组患者的治疗总有效率达92.31%,明显高于参照组(69.23%),对比差异显著性检验P<0.05。研究组患者并发症发生率为3.85%,明显低于参照组(19.23%),对比差异显著性检验P<0.05;研究组患者随访1个月的复发率为0%,明显低于参照组(15.38%),对比差异显著性检验P<0.05。结论:地塞米松联合抗炎、抗感染治疗虹膜睫状体炎,可提升临床有效行,降低并发症发生率、复发率,效果可靠。

Objective: To analyze the clinical value of dexamethasone combined with anti-inflammatory and anti-infective therapy in iridocyclitis. Methods: 52 patients with iridocyclitis were randomly divided into two groups: the reference group(26 cases) and the study group(26 cases). The patients in the reference group were treated with dexamethasone only after operation, and the patients in the study group were treated with dexamethasone combined with anti-inflammatory and anti infection treatment after operation. Results: The total effective rate of the study group(92.31%) was significantly higher than that of the reference group(69.23%)(P<0.05). The incidence of complications in the study group(3.85%) was significantly lower than that in the reference group(19.23%) with a significant difference(P<0.05);the recurrence rate in the study group was significantly lower than that in the reference group(15.38%) with a one month follow-up(P<0.05). Conclusion: Dexamethasone combined with anti-inflammatory and antiinfective treatment of iridocyclitis can improve the clinical efficacy, reduce the incidence of complications, recurrence rate, the effect is reliable.